Connect with us

Technology

Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab

Published

on

Helping researchers to move from discovery to breakthrough up to 8x faster by combining AI, automation and innovation from across Danaher’s ecosystem of industry-leading technologies

WASHINGTON, Oct. 7, 2026 /PRNewswire/ — Danaher Corporation (NYSE: DHR) today announced plans to launch its first AI-powered autonomous lab, designed to help researchers develop custom antibodies and other molecular tools faster and more efficiently. Expected to operate at scale in early 2027, the lab will combine artificial intelligence, robotics and technologies from several Danaher operating companies in one connected workflow. It is the first step in a broader Danaher initiative to create smart instruments, integrated workflows and autonomous labs that accelerate scientific research.

Danaher’s first AI-powered autonomous lab is designed to deliver:

Speed: Up to 8x faster discovery of affinity reagents, helping researchers get from idea to breakthrough soonerScale: Unlocking up to a tenfold increase in annual reagent generation, from tens to hundreds of reagents per year as the lab scalesQuality: Each design built in the lab would also be verified, tested and fed back to improve the next, without trading speed for scientific rigorSustainability: Over time, this approach is expected to complement traditional immunization-based methods used in the discovery of antibodies and other research tools

“The autonomous lab reflects the kind of progress Danaher is uniquely positioned to deliver,” said Julie Sawyer Montgomery, President and Chief Executive Officer of Danaher. “By applying our science, technology and culture of continuous improvement, we can help turn promising ideas into validated systems faster. It is an important step toward a future where AI, automation and intelligent systems dramatically accelerate the journey from discovery to impact.”

Based at Abcam, a Danaher company, the lab uses AI to help create new affinity reagents, including antibodies, then builds and tests each one, feeding every result back into the model to improve the next design. The lab brings together industry-leading technologies and expertise from several Danaher operating companies, including Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices, in one connected workflow. The device orchestration and robotic automation is the result of collaborative work with Automata*. This continuous design-make-test-learn loop can run in a fraction of the time it takes today, without trading speed for scientific rigor. This approach applies the same test-and-verify discipline of continuous improvement long used across Danaher operations to an AI-enabled laboratory environment. The lab is set to be an early proof point for how Danaher’s smart instruments, AI-ready data, and expert agentic systems can accelerate scientific discovery and medical progress.

“This lab represents a new model for scientific discovery, where AI, automation and human expertise work together in a continuous learning cycle,” said JC Gutierrez-Ramos, Senior Vice President and Chief Science Officer of Danaher. “Speed is what supercharges that cycle. Every result sharpens the next design, so the faster each loop runs, the faster discovery compounds. The lab is designed to deliver up to eight times faster progress from idea to validated reagent and up to a tenfold increase in reagent generation, while scientists continue to make the key decisions. That frees them to focus on the complex scientific challenges where human insight matters most.”

The lab is an example of a broader program across Danaher intended to create a fleet of smart instruments that are easier to integrate and control programmatically, produce AI-ready data, and include expert-level agentic systems designed to simplify operation, improve data quality and generate deeper insights. These intelligent devices can then be connected to create integrated workflows and autonomous labs that execute design-make-test-learn cycles. The approach also supports a shift toward more predictive and standardized research workflows, with models helping prioritize the most promising designs before they are made and robotics supporting more consistent experimentation.

The platform reflects an important milestone in the Company’s continued investment in connected science at a global scale: technologies designed to help researchers move from scientific question to validated answer with greater speed, consistency and confidence.

FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION
Statements in this release that are not strictly historical, including statements regarding the Company’s AI-powered autonomous lab, the anticipated timing, performance, capabilities and benefits of the platform, the development and deployment of smart instruments, integrated workflows and autonomous labs, and the expected impact of these technologies on biomedical research and scientific discovery, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are “forward-looking” statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we have incurred to finance the acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of Masimo), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2026. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to advancing the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve many of their most complex scientific and clinical challenges—accelerating the moment scientific discovery becomes human impact. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. That’s Innovation at the speed of life. Explore more at www.danaher.com.

*Automata received an investment from DHR in Jan 2026

View original content:https://www.prnewswire.com/news-releases/danaher-accelerates-life-sciences-research-with-new-ai-powered-autonomous-lab-302900563.html

SOURCE Danaher Corporation

Continue Reading

Technology

ThinkAndor® Now Available in Epic Toolbox for Ambient Nursing Documentation

Published

on

By

Helping Health Systems Address Nursing Shortages, Burnout, & Documentation Burden Through Ambient AI

ORLANDO, Fla., Oct. 7, 2026 /PRNewswire/ — Andor Health, the AI-native healthcare infrastructure setting the standard, announces that ThinkAndor® is now Epic Toolbox designated for Ambient Voice Recognition: Nursing Flowsheets.

Nurses often spend hours documenting care, extending charting beyond scheduled shifts and lose time for direct patient care. As organizations seek new ways to support and retain clinical staff, ambient documentation is emerging as a key technology to reduce administrative burden and improve their experience.

ThinkAndor® uses ambient AI and voice recognition to capture clinical conversations naturally and transform them into structured nursing documentation directly within Epic Rover. By supporting documentation in the background, ThinkAndor® gives nurses back time with patients by enabling quicker charting, all within their existing workflows.

“Healthcare organizations are looking for meaningful ways to support their nursing workforce while maintaining high-quality patient care,” said Mary Morin, Chief Nursing Officer at Andor Health. “Ambient AI can significantly reduce documentation burden and enable nurses to focus more of their time and attention on patients. Our Epic Toolbox designation for Ambient Nursing Flowsheets reflects our commitment to delivering these capabilities directly within nursing workflows.”

Epic Toolbox lists applications that meet Epic’s recommended practices for specific integration categories. ThinkAndor’s designation in the Ambient Nursing Flowsheets category reflects its alignment with these practices and its ability to support health systems implementing ambient nursing documentation at scale.

Learn more about the limitless possibilities of ThinkAndor® at https://andorhealth.com/thinkandor/.

Epic and Rover are registered trademarks of Epic Systems Corporation.

About Andor Health
Andor Health revolutionizes clinical care through agentic AI-powered virtual care experiences across the care continuum. Our virtual care experiences empower healthcare providers with actionable insights & ambient monitoring to deliver care at scale, with proven return on investment. ThinkAndor®, the #1 AI-native services infrastructure for healthcare, leverages AI agents to harness generative AI unlocking data stored in various systems, including electronic medical records, biometric devices, & other signals to deliver actionable intelligence in real time to care teams. By optimizing communication workflows, ThinkAndor® accelerates time to treatment, decreases clinician burnout, and drives better patient outcomes. 

For more information, visit Andor Health or follow us on LinkedIn and X.  

Media Contact:  
Andor Health  
Jennifer Skitsko – SVP, Marketing  
Email: Jennifer.Skitsko@andorhealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/thinkandor-now-available-in-epic-toolbox-for-ambient-nursing-documentation-302900231.html

SOURCE Andor Health

Continue Reading

Technology

BetMGM Voted Most Trusted Online Casino Brand* in the 2026 BrandSpark Most Trusted® Awards

Published

on

By

Independent study of more than 35,000 U.S. consumers identifies BetMGM as the most trusted online casino brand* in America

JERSEY CITY, N.J., Oct. 7, 2026 /PRNewswire/ — BetMGM, a leading sports betting and iGaming operator, announced it has been voted the Most Trusted Online Casino Brand* in America in the 2026 BrandSpark® American Trust Study, presented in partnership with Newsweek.

Creative assets available here

“In an industry where fairness and security are top of mind for our players, trust is the foundation of everything we do,” said Adam Greenblatt, Chief Executive Officer, BetMGM. “This recognition reflects our commitment to the highest standards of the regulated market. From our industry-leading game portfolio and responsible gambling tools to the security and reliability of our platform, we’re committed to providing players with an exceptional online casino experience.”

The recognition is based on the 2026 BrandSpark American Trust Study, an independent survey of more than 35,000 U.S. consumers that measures trust across hundreds of brands and categories. BetMGM was identified as a top trusted online casino brand by American consumers, reflecting the company’s continued focus on delivering a premium, reliable and secure online casino.

BrandSpark’s analysis found that trust in BetMGM reflects strong consumer perceptions of quality, reliability, dependable payouts, and overall platform credibility. The brand performed particularly well among higher-income and older demographics, underscoring its appeal to consumers who prioritize trust, security and confidence in their gaming platform.

The award further reinforces BetMGM’s position as one of the most recognized and trusted names in online gaming. In recent years, BetMGM has earned multiple Casino Operator of the Year awards from SBC, EGR and the American Gambling Awards.

BetMGM’s award-winning online casino is home to over 7,000 titles across North American markets and one of the largest state-by-state exclusive progressive jackpot networks. BetMGM’s jackpot network currently consists of over 25 games including popular titles such as MGM Grand Millions, Bison Fury and 15 Lanterns. Players can earn BetMGM Rewards Points and Tier Credits by playing at BetMGM Casino. BetMGM Rewards Points can be redeemed for digital bonuses, MGM Rewards Points and Marriott Bonvoy Points.

As BetMGM continues to expand into new markets and introduces new features, responsible gambling remains a key focus. Additionally, BetMGM is proud to provide resources to help customers play responsibly, including GameSense, an industry-leading program developed and licensed to BetMGM by the British Columbia Lottery Corporation. Through the integration within BetMGM’s mobile and desktop platforms, customers can receive the same GameSense experience they have grown to rely on at MGM Resorts properties. GameSense complements BetMGM’s existing responsible gambling tools which serve to provide customers with an entertaining and safe digital experience.

For more information on BetMGM, follow @BetMGM on X.

*Voted most trusted Online Casino brand (in a tie) by American consumers based on the 2026 BrandSpark® American Trust Study.

Gambling problem? Call 1-800-GAMBLER or 1-800-MY-RESET (Available in the US), 877-8-HOPENY or text HOPENY (467369) (NY), 1-800-327-5050 (MA), 1-800-BETS-OFF (IA). 21+ only. Please Gamble Responsibly. See BetMGM.com for Terms. Subject to eligibility requirements. In partnership with Kansas Crossing Casino and Hotel. 

Statements in this release that are not historical facts are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and involve risks and/or uncertainties, including those described in MGM Resorts’ public filings with the Securities and Exchange Commission. Forward-looking statements can be identified by the use of forward-looking terminology such as “believes,” “expects,” “could,” “may,” “will,” “should,” “seeks,” “likely,” “intends,” “plans,” “pro forma,” “projects,” “estimates” or “anticipates” or the negative of these words and phrases or similar words or phrases that are predictions of or indicate future events or trends and that do not relate solely to historical matters. MGM Resorts and BetMGM have based forward-looking statements on management’s current expectations and assumptions and not on historical facts. Examples of these statements include, but are not limited to, MGM Resorts and BetMGM’s expectations regarding the promotion and related offerings. These forward-looking statements involve a number of risks and uncertainties. Among the important factors that could cause actual results to differ materially from those indicated in such forward-looking statements include the risk that the promotion and related offerings are not available in the manner described herein, risks related to the effects of economic conditions and market conditions in the markets in which MGM Resorts and BetMGM operate and competition with other destination travel locations throughout the United States and the world, the design, timing and costs of expansion projects, risks relating to international operations, permits, licenses, financings, approvals and other contingencies in connection with growth in new or existing jurisdictions and additional risks and uncertainties described in MGM Resorts’ Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports). In providing forward-looking statements, neither MGM Resorts nor BetMGM is undertaking any duty or obligation to update these statements publicly as a result of new information, future events or otherwise, except as required by law. If MGM Resorts or BetMGM update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those other forward-looking statements.

About BetMGM 
BetMGM is a market-leading sports betting and gaming entertainment company, pioneering the online gaming industry. Born out of a partnership between MGM Resorts International (NYSE: MGM) and Entain Plc (LSE: ENT), BetMGM has exclusive access to all of MGM’s U.S. land-based and online sports betting, major tournament poker, and online gaming businesses. Utilizing Entain’s U.S.-licensed, state-of-the-art technology, BetMGM offers sports betting and online gaming via market-leading brands including BetMGM, Borgata Casino, Party Casino and Party Poker. Founded in 2018, BetMGM is headquartered in New Jersey. For more information, visit https://www.betmgminc.com.

About BrandSpark International
BrandSpark International is a leading market research firm that conducts the annual BrandSpark American Trust Study in partnership with Newsweek, surveying more than 35,000 qualified American shoppers across hundreds of product and service categories. The BrandSpark Most Trusted Awards are 100 percent consumer-voted and reflect direct, unaided consumer perceptions of brand trust.

View original content to download multimedia:https://www.prnewswire.com/news-releases/betmgm-voted-most-trusted-online-casino-brand-in-the-2026-brandspark-most-trusted-awards-302900404.html

SOURCE BetMGM

Continue Reading

Technology

Moët Hennessy, Analog Devices and UC Davis Join Forces to Advance Wine Production Through Breakthrough Chemical Signature Detection Technology Leveraging AI

Published

on

By

Researchers have demonstrated the ability to identify the complex chemical signatures emitted from grapes and wine to predict quality risks in wine production faster and more affordably than conventional methods.

PARIS and WILMINGTON, Mass., Oct. 7, 2026 /PRNewswire/ — Moët Hennessy, the wine and spirits division of LVMH, Analog Devices, Inc. (ADI), a global semiconductor leader, and University of California, Davis, a world-renowned leading research university, today announced a groundbreaking joint effort to deploy a new generation of technology aimed at enhancing wine quality and supporting the long-term vitality of vineyards.

The collaboration builds on a breakthrough technology that has its roots in early research at the Massachusetts Institute of Technology (MIT). Today, ADI continues to advance this technology platform for analyzing chemical signatures across a broad range of applications and, together with teams from Moët Hennessy and UC Davis, is exploring its use in viticulture and winemaking. The joint effort aims to detect and interpret volatile chemical signatures emitted by grapevines, juice, and wine, giving viticulture and winemaking teams much earlier insights into biological processes and potential quality risks.

A world first demonstration: predicting Fresh Mushroom Aroma before it develops 
The collaboration’s first major achievement addresses one of the wine industry’s most complex quality challenges: Fresh Mushroom Aroma (FMA). Researchers at Moët Hennessy’s Robert-Jean de Vogüé Research Center have built a unique library of samples and associated data to train machine learning algorithms to recognize the chemical signatures associated with this quality risk.

For the first time, the technology successfully identified samples presenting an elevated risk of developing FMA at an early stage, well before the defect would traditionally be detected. This breakthrough creates entirely new possibilities for proactive quality management, enabling earlier interventions and fundamentally changing how quality risks may be monitored throughout the winemaking process.

Powered by ADI’s sensing and machine learning platform, the system analyzes a broad spectrum of chemical information and uses AI to identify which signals matter most, revealing patterns that may otherwise go undetected. Rather than looking only for predefined conditions, the platform continuously learns from complex chemical data, enabling a deeper understanding of biological activity and emerging quality risks.

A technology platform with multiple future applications 
Beyond FMA, the organizations view this technology as a scalable platform for living systems analysis, with potential applications wherever biological processes generate meaningful chemical signatures that can be measured, interpreted and acted upon. Additional applications being researched include early detection of vine diseases, soil assessment, and identification of other defects, especially those linked to climate change and related events (e.g., wildfires).

The goal is to support, not replace, human expertise by equipping researchers, viticulturists, and winemakers with decision-support tools for earlier detection and deeper insights. The technology is designed to augment the expertise of growers and winemakers, providing additional information and context while preserving the craftsmanship, experience, and judgment that remain central to exceptional winemaking.

An international collaboration uniting technology, AI and life sciences
The effort combines complementary expertise from:

Moët Hennessy, the world leader in premium and super-premium wines and spiritsADI, a global semiconductor leader that bridges the physical and digital worlds to enable breakthroughs at the Intelligent Edge; ADI Health Solutions, ADI’s business unit focused on developing AI-driven solutions that contribute to the health of people and the planetUC Davis, internationally recognized as a global leader in viticulture and enology

Together, the organizations aim to unlock new capabilities for observing, understanding and interpreting the complex grape and wine matrix in support of quality and resilience across the wine industry. Beyond this initial collaboration, ADI intends to make this technology broadly available for future industrial applications, while Moët Hennessy and UC Davis are exploring how shared reference libraries could benefit the wider grape and wine industry.

Manuel Reman, member of the Moët Hennessy Executive Committee, overseeing R&D, and Member of the Comité Champagne: “This breakthrough marks the beginning of a new chapter for viticulture and winemaking. We can rapidly detect and interpret the chemical language of grapes and wine to anticipate quality risks before they become visible. Beyond a technological achievement, this opens an entirely new way of understanding and working, one that will help us produce exceptional wines while building greater resilience for the future.”

Max Shulaker, Chief of ADI’s Health Solutions Business Unit: “This collaboration unites world-class expertise in cutting-edge AI-enabled sensing systems and viticulture to accomplish something previously impossible: reading the chemical language that living systems emit themselves. By recognizing these signatures before conventional methods can, this technology can help winemakers shift from reacting to quality risks to anticipating them. Our first breakthrough addresses Fresh Mushroom Aroma, but it marks the beginning of a much broader platform for understanding living systems, one that can improve quality and resilience in ways that are just now being explored and unlocked.”

Ben Montpetit, Ph.D, UC Davis: “In the face of major global challenges, the continued advancement and resilience of the grape and wine sectors will depend on two things: better knowledge and people equipped to put that knowledge into practice. What is especially powerful about this collaboration is that we are advancing both. We are developing technology that can give viticulturists and winemakers the right information at the right time to make informed decisions, while also training the next generation of experts who will know how to interpret and act on those insights.”

About Moët Hennessy 
Moët Hennessy is the wines and spirits division of the LVMH group, which also owns renowned vineyards grouped under the “LVMH Vins d’Exceptions” entity. Comprising twenty-five Maisons, internationally recognized for their rich terroirs, the quality of their products, and the artisanal expertise they embody, Moët Hennessy has been committed for many years to an environmental and social program, “Living Soils Living Together.”

About Analog Devices, Inc.
Analog Devices, Inc. (NASDAQ: ADI) is a global semiconductor leader that bridges the physical and digital worlds to enable breakthroughs at the Intelligent Edge. ADI combines analog, digital, AI, and software technologies into solutions that combat climate change, reliably connect humans and the world, and help drive advancements in automation and robotics, mobility, healthcare, energy and data centers. With revenue of more than $11 billion in FY25, ADI ensures today’s innovators stay Ahead of What’s Possible. Learn more at www.analog.com and on Linkedin and X. 

About UC Davis
Established in 1908, UC Davis has continually branched out, challenged the way things are done, and gained recognition for solving complex problems related to health, environment, culture and society. Our 5,300-acre campus borders the city of Davis, a vibrant college town of about 68,000 people. UC Davis is among the most comprehensive campuses in the University of California system, with four colleges and six professional schools that offer over 100 undergraduate majors and more than 100 graduate and professional degrees. UC Davis enrolls about 40,000 students from over 110 countries and contributes at least $13 billion to the California economy each year. In the 2024-25 fiscal year, the university exceeded $1 billion in research funding for the third consecutive year.

PRESS & MEDIA 

Moët Hennessy
Quentin DURAND
Head of Corporate Communications
qdurand@moethennessy.com
+33 7 84 28 01 43

Analog Devices
Ferda Millan 
Global PR and External Communications 
CorpComm@analog.com
+1 (408) 373-1854 

Jeff Ambrosi
Senior Director, Investor Relations
Investor.Relations@analog.com
+1 (781) 461-3282

UC Davis
Ben Montpetit, Ph.D
Professor and Chair, Department of Viticulture and Enology
benmontpetit@ucdavis.edu

View original content to download multimedia:https://www.prnewswire.com/news-releases/moet-hennessy-analog-devices-and-uc-davis-join-forces-to-advance-wine-production-through-breakthrough-chemical-signature-detection-technology-leveraging-ai-302901173.html

SOURCE Analog Devices, Inc.

Continue Reading

Trending